Compare · ILMN vs YDES
ILMN vs YDES
Side-by-side comparison of Illumina Inc. (ILMN) and YD Bio Limited (YDES): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ILMN and YDES operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $30.34B, about 93.9x YDES ($323.0M).
- Over the past year, ILMN is up 68.3% and YDES is down 52.0% - ILMN leads by 120.3 points.
- ILMN has been more active in the news (15 items in the past 4 weeks vs 1 for YDES).
- ILMN has more recent analyst coverage (25 ratings vs 0 for YDES).
- Company
- Illumina Inc.
- YD Bio Limited
- Price
- -
- -
- Market cap
- $30.34B
- $323.0M
- 1M return
- -29.07%
- -20.61%
- 1Y return
- +68.32%
- -52.00%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2000
- News (4w)
- 15
- 1
- Recent ratings
- 25
- 0
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Latest ILMN
- Illumina Wins Virtual Cell Challenge, Powered by Billion Cell Atlas
- Amendment: SEC Form SCHEDULE 13G/A filed by Illumina Inc.
- Director Meister Keith A. sold $61,093,041 worth of shares (280,091 units at $218.12) (SEC Form 4)
- VP, Chief Accounting Officer Ericksen Scott D sold $58,142 worth of shares (267 units at $217.76), decreasing direct ownership by 2% to 14,029 units (SEC Form 4)
- SVP, Chief Technology Officer Barnard Steven covered exercise/tax liability with 360 shares, decreasing direct ownership by 0.88% to 40,567 units (SEC Form 4)
- VP, Chief Accounting Officer Ericksen Scott D covered exercise/tax liability with 150 shares, decreasing direct ownership by 1% to 14,296 units (SEC Form 4)
- SVP, Chief People Officer Leckman Patricia covered exercise/tax liability with 208 shares, decreasing direct ownership by 0.98% to 21,120 units (SEC Form 4)
- Chief of Global Operations Pegels Kevin Carl covered exercise/tax liability with 604 shares, decreasing direct ownership by 2% to 28,434 units (SEC Form 4)
- Illumina advances MRD research portfolio with ultrasensitive duplex sequencing technology
- Director Meister Keith A. sold $66,560,212 worth of shares (281,433 units at $236.50) (SEC Form 4)
Latest YDES
- YD Bio Announces FDA Grant of INTERACT Meeting Request for YDB-LMSCEV-001, an Investigational Extracellular Vesicle Candidate for Dry Eye Disease
- YD Bio and EG BioMed Partner with JoiiUp to Launch AI-Driven Cancer Risk Assessment for Corporate Wellness Programs
- SEC Form 4 filed by YD Bio Limited
- SEC Form 4 filed by YD Bio Limited
- YD Bio and EG BioMed Launch AI-Based 10-Cancer Risk Factor Assessment
- CEO Shen Ethan Phd bought $48,895 worth of Ordinary Shares (12,700 units at $3.85), increasing direct ownership by 0.11% to 11,258,331 units (SEC Form 4)
- CEO Shen Ethan Phd bought $12,183 worth of Ordinary Shares (3,100 units at $3.93), increasing direct ownership by 0.03% to 11,245,631 units (SEC Form 4)
- CEO Shen Ethan Phd bought $67,447 worth of Ordinary Shares (18,378 units at $3.67), increasing direct ownership by 0.16% to 11,242,531 units (SEC Form 4)
- YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026
- YD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health Institute